Manufacturers of ultrasound systems, vital sign monitors, and organ transplant devices were targeted by three device-related warning letters issued this week.
[Editors' note: Check out Medtech Insight's US FDA Warning Letter Data Tracker here.]
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.
The reason for the correction is that if the device momentarily activates but does not cut or staple tissue, providers can be inadvertently locked out during surgical procedures. When a lockout occurs, additional steps are required to open the device and remove it from tissue.
A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.
Dexcom has recalled several models of its glucose monitoring receivers due to a speaker glitch that may suppress vital blood sugar alerts. The FDA designated the recall, which affects thousands of devices, as class I.
